What You Think About Getting Old Impacts Your Health, Quality of Life According to New Orb Media Reporting

Food and Healthcare Press Releases Wednesday June 13, 2018 12:34
WASHINGTON--13 Jun--PRNewswire/InfoQuest
  • Rapidly Aging Global Population At Risk Without Simple Attitude Shift
New Orb Media Inc. reporting and data analysis [ https://www.orbmedia.org/agewell ] shows a strong connection between how we view old age, how well we age and the effects seen across world cultures.

Individuals with a positive attitude towards old age are likely to live longer and in better health than those with a negative attitude. And those with a negative view of aging are more likely to suffer a heart attack, a stroke or die several years sooner.

Older people in countries with low levels of respect for the elderly are at risk for worse mental and physical health and higher levels of relative poverty.
Orb Media compiled data from 150,000 people in 101 countries to learn about their levels of respect for older people. The data show the level of respect varies significantly from country to country.

Healthy aging is increasingly important: Outside of Africa, countries everywhere are aging rapidly. If population trends continue, by 2050 nearly one out of six people in the world will be over 65, and close to half a billion will be older than 80.

Orb Media is pleased to partner with members of the Orb Media Network (OMN), a group of global agenda-setting media which collaborate to simultaneously publish stories together that catalyze global dialogue on critical issues, focusing the attention of government, industry, researchers, civil society, and the public.

OMN members include SVT (Sweden), Die Zeit (Germany), The Hindu (India), Folha de Sao Paulo (Brazil), Tempo Media Group (Indonesia), El Tiempo (Columbia), BBC (United Kingdom), Cadena SER-Prisa (Spain), CBC (Canada), Dhaka Tribune (Bangladesh), Deutsche Welle (Germany), and YLE (Finland).

About Orb Media

Orb Media is a nonprofit journalism organization that reports on issues that matter to billions of people around the globe. We publish our work simultaneously with a global network of leading media organizations to catalyze global public dialogue to generate citizen-driven change. Fusing original research, data analysis, on-the-ground reporting, and an engaged public, Orb Media produces agenda-setting stories about the challenges we face together as one world. Orbmedia.org/agewell.

Media Contact: Lara Kline, larak@orbmedia.org .
Photo - https://mma.prnewswire.com/media/704341/Orb_Media___Family.jpg
Logo - https://mma.prnewswire.com/media/652865/Orb_Media_Logo.jpg

Latest Press Release

Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology

- Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration IP necessary to correct genetic defects in gene therapy patients - Merck to...

Kaneka officially starts continuous manufacturing under GMP

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Mamoru Kadokura) have installed continuous manufacturing equipment to be applied to pharmaceutical products at Kaneka Singapore Co. (Pte.) Ltd, (Headquarters: Singapore; President: Kazuhiko...

TIENS Group opens new high-tech Experience Store in Shenzhen

TIENS Group, one of leading corporations in the Healthcare industry, unveiled a new high-tech Customer Experience Store in Shenzhen. Li Jinyuan, founder and chairman of TIENS group, announced the official opening of its first store in the world on August...

Sotera Health#s Nordion completes the sale of its medical isotopes business to BWXT

- Nordion's increased focus on gamma technologies supports Sotera Health's company-wide commitment to Safeguarding Global Health(TM) Sotera Health LLC, the world's leading, fully integrated protector of global health, today announced the closing of the...

Menarini Ricerche to Sponsor Cancer Trial in Acute Myeloid Leukemia in USA

Menarini Ricerche, a company of the Menarini Group, announced today that the sponsorship of the ongoing Phase I/II study that is investigating MEN1703/SEL24 for the treatment of patients with relapsed/refractory (R/R) AML in the USA has been transferred...

Related Topics